![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » RETRONECTIN TO BE USED IN AUSTRALIA FOR TRIALS OF MULTIPLE MYELOMA THERAPY
RETRONECTIN TO BE USED IN AUSTRALIA FOR TRIALS OF MULTIPLE MYELOMA THERAPY
Takara Bio has entered into a license and material transfer agreement with the Peter MacCallum Cancer Centre in Melbourne, Australia to supply Takara Bio's RetroNectin for use in a Phase I clinical trial of multiple myeloma (MM). Six patients are expected to be enrolled in this Phase I trial.
In the Peter MacCallum Cancer Centre protocol, T cells collected from MM patients are retrovirally transduced in vitro utilizing the RetroNectin method with a gene encoding a chimeric receptor that specifically recognizes the oligosaccharide antigen, Lewis-Y, expressed on malignant MM cells.
Following expansion of transduced T cells in the laboratory; MM patients will be infused with these modified T cells. The gene-transduced T cells express the Lewis-Y-specific chimeric receptor, which recognizes the Lewis-Y antigen on malignant MM cells, inducing the T cells to specifically attack the malignant cells. Based on this concept, the principal investigator has shown that the growth in mice of human ovarian tumor cells expressing Lewis-Y antigen is significantly inhibited in 89 percent of mice treated with genetically-modified anti-Lewis-Y-specific T cells.
This is the 41st clinical trial in which the RetroNectin method has been used, and is the first time the RetroNectin method has been used a clinical trial conducted outside Japan, Europe or the U.S. Currently, ex vivo gene therapy is expanding throughout the world as an effective treatment method for several incurable diseases.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct